

References

I-86

1. Sciafani F, Cunningham D. Bevacizumab in elderly patients with metastatic colorectal cancer. *Journal of Geriatric Oncology*. 2014 Jan;5(1):78-88.
2. Lilenbaum RC. Systemic therapy for the initial management of advanced non-small cell lung cancer without a driver mutation. UpToDate. Last Update Dec 21, 2015.
3. Batchelor T, Shih HA, Carter BS. Management of recurrent high-grade gliomas. UpToDate. Last Update Jan 06, 2016.
4. Pujol JL, Lavole A, Quoix E, et al. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. *Annals of Oncology*. 2015;908-914.
5. Yonezawa H, Hirano H, Uchida H, et al. Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. *Molecular AND Clinical Oncology* 2016:105-110.
6. Bevacizumab (Avastin®) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 2/2019.
7. Mvasi (bevacizumab-awwb) solution for intravenous infusion [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 09/2017.
8. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Bevacizumab. 2019.
9. National Comprehensive Cancer Network (NCCN). Bevacizumab. NCCN Drugs and Biologics Compendium®. 2019.
10. Micromedex®Solutions Compendia. 2019. Bevacizumab.
11. Franchi M, Barni S, Tagliabue G, et al. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. *Oncologist*. 2019;24(3):358-365.
12. Zirabev (bevacizumab-bvzr) injection, for intravenous use [package insert]. Pfizer Inc. New York, NY. Revised 06/2019.